Savara Quarterly Cash Flow Statement
NASDAQ: SVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
4.92+0.09 (+1.86%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Savara free cash flow
In the quarter ended Jun 30, 2026, Savara generated -$29.7 million of operating cash flow and spent $222,000 on capital expenditures. That left free cash flow of -$30.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Savara cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -40.23M | -37.28M | -32.24M | -29.56M | -30.40M | -26.64M | -29.04M | -24.25M | -22.24M | -20.35M | -16.10M | -16.60M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 28.00K | 24.00K | -11.00K | 35.00K | 34.00K | 30.00K | 32.00K | 33.00K | 33.00K | 32.00K | 32.00K | 30.00K |
| Stock-Based Compensation | 7.76M | 10.73M | 5.36M | 3.42M | 2.67M | 2.97M | 3.04M | 2.37M | 2.20M | 2.26M | 1.36M | 995.00K |
| Change in Working Capital | 1.48M | -639.00K | -2.35M | 712.00K | 880.00K | 859.00K | 974.00K | -680.00K | -2.92M | 243.00K | -1.60M | 765.00K |
| Operating Cash Flow | -29.75M | -33.05M | -25.06M | -22.53M | -26.26M | -27.19M | -23.28M | -22.67M | -22.50M | -20.64M | -15.60M | -13.16M |
| Capital Expenditures | -222.00K | -54.00K | -2.00K | -2.00K | -15.00K | -3.00K | 9.00K | -3.00K | -21.00K | -10.00K | -24.00K | -43.00K |
| Investing Cash Flow | 32.60M | 38.78M | -93.56M | 21.47M | 24.33M | 29.33M | 17.89M | -98.17M | 29.54M | 10.79M | 6.57M | -56.59M |
| Debt Issued | — | — | 0 | 0 | 0 | 29.60M | — | — | — | — | — | — |
| Debt Repaid | — | — | 0 | 1.00K | 0 | -27.23M | — | — | — | — | — | — |
| Financing Cash Flow | 189.00K | -195.00K | 135.56M | -23.00K | -49.00K | 2.32M | -843.00K | 118.32M | 55.00K | 49.00K | 7.89M | 74.75M |
| Net Change in Cash | 3.01M | 5.61M | 16.90M | -1.16M | -2.12M | 4.43M | -6.30M | -2.44M | 7.08M | -9.80M | -1.10M | 4.95M |
| Free Cash Flow | -29.97M | -33.10M | -25.06M | -22.53M | -26.28M | -27.19M | -23.27M | -22.67M | -22.52M | -20.65M | -15.63M | -13.20M |
This table shows 12 quarterly periods of Savara's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SVRA's reporting calendar. What is a cash flow statement?